Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 20/20 | 0.77 |
| ▸ | OXTR | P30559 | 12/20 | 0.77 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697681 | 0.94 | AVPR1A (0.79) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL38380 | 0.90 | AVPR1A (0.88) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4837407 | 0.90 | AVPR1A (0.90) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4835384 | 0.90 | AVPR1A (0.83) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2598091 | 0.87 | AVPR1A (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL4835403 | 0.87 | AVPR1A (0.85) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL31737367 | 0.87 | AVPR1A (1.00) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL29580282 | 0.86 | AVPR1A (0.99) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL5428661 | 0.86 | AVPR1A (0.99) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL45615 | 0.85 | AVPR1A (0.84) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948662-A2 | TRICYCLIC COMPOUNDS USEFUL AS OXYTOCIN RECEPTOR AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-07-30 | — | — | EP | claimed |
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | claimed |
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | WYETH (US) | 2007-05-24 | — | — | US | claimed |
| WO-2007050353-A2 | TRICYCLIC COMPOUNDS USEFUL AS OXYTOCIN RECEPTOR AGONISTS | WYETH (US) | 2007-05-03 | — | — | WO | claimed |
| JP-2007504263-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1660501-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2006-05-31 | — | — | EP | claimed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | claimed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | claimed |
| US-9125862-B2 | Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | Institut National de la Sante et de la Rechereche Medicale (INSERM) (FR) | 2015-01-01 | — | — | US | disclosed |
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | WYETH (US) | 2007-05-24 | — | — | US | disclosed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117794-A1 | Methods of treatment using oxytocin receptor agonists | OXTR, AVPR1A, PRLHR | AVPR1A 2/4885OXTR 1/4885AVPR2 8/4885 |
| US-20150005229-A1 | Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient | OXTR, OPRL1, GHRHR | AVPR1A 10/4885OXTR 1/4885AVPR2 12/4885 |
| US-20070197608-A1 | Piperazines as oxytocin agonists | OXTR, OPRL1, AVPR2 | AVPR1A 6/4885OXTR 1/4885AVPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.